8-Bromo-3-Methylxanthine CAS 93703-24-3 Linagliptin Intermedia Puritas ≥99.0% Factory

Description:

Nomen chemicum: 8-Bromo-3-Methylxanthine

CAS: 93703-24-3

Puritas: ≥99.0%

Aspectus: Alba et lux Yellow pulveris

Intermedia pro Linagliptin (CAS: 668270-12-0) tractationis genus II diabete mellitus

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple Linagliptin et intermedia:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermedia CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine CAS 666816-98-4
2-(Chloromethyl) -4-Methylquinazoline CAS 109113-72-6
(R) -3-(Boc-Amino) piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Chemical Properties:

Nomen chemicum	8-Bromo-3-Methylxanthine
Synonyma	8-Bromo-3-Methyl-3,7-dihydro-1H-purinum-2,6-dione
CAS Number	93703-24-3
CATTUS Number	RF-PI501
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C6H5BrN4O2
M. Pondus	245.03
Liquescens punctum	300℃(lit.)
Density	1.974g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad lux Yellow pulveris
Puritas	≥99.0%
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.50%
una immunditia	≤0.50%
Totalis immunditias	≤1.0%
Metalla gravis	≤20ppm
Test Standard	Enterprise Standard
Consuetudinem	Intermedia pro Linagliptin (CAS: 668270-12-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

8-Bromo-3-Methylxanthinum (CAS: 93703-24-3) substituta derivatio Xanthine.Ad synthesim Linagliptin adhiberi potest (CAS: 668270-12-0), quae nova potens et selectiva dipeptidyli peptidase-4 (DPP-4) inhibitor cum potentia in usu diabete generis tractandi.Probatum est ab US FDA mense Maio 2011 ad tractationem Typus 2 diabetae cum victu et exercitatione. Originator Boehringer Ingelheim est (United States).